PrefER Selected Publications

PrefER Selected Publications

Following is a listing of select published papers over the last 10 years that represent best-practice applications and methods development.

Selected Publications

Johnson FR, DiSantostefano RL, Yang JC, Reed SD, Streffer J, Levitan B. Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms. Value Health. 2019 Sep;22(9):1063-1069. doi: 10.1016/j.jval.2019.03.022. Epub 2019 Jul 20.  PMID: 31511183

Havrilesky LJ, Yang JC, Lee PS, Secord AA, Ehrisman JA, Davidson B, Berchuck A, Darcy KM, Maxwell GL, Reed SDPatient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. Cancer. 2019 Aug 27. doi: 10.1002/cncr.32447. [Epub ahead of print] PMID: 1454432

Johnson FR, Scott FI, Reed SD, Lewis JD, Bewtra M.  Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations.  Value Health. 2019 Jun;22(6):684-692. doi: 10.1016/j.jval.2019.03.011. PMID: 31198186

Bewtra M, Reed SD, Johnson FR, Scott FI, Gilroy E, Sandler RS, Chen W, Lewis JD. Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents.  Clin Gastroenterol Hepatol. 2019 May 14. pii: S1542-3565(19)30520-8. doi: 10.1016/j.cgh.2019.05.010. [Epub ahead of print]  PMID: 31100456

Johnson FR, Yang JC, Reed SDThe Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments.  Value Health. 2019 Feb;22(2):157-160. doi: 10.1016/j.jval.2018.07.876. Epub 2018 Sep 27.  PMID:  30711059

Fairchild AO, Reed SD, Johnson FR, Anglin G, Wolka AM, Noel RA. What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. J Dermatolog Treat. 2017 Jun 7:1-7. Available at: http://www.tandfonline.com/doi/full/10.1080/09546634.2017.1329499

Marshall DA, Gonzalez JM, MacDonald KV, Johnson FREstimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. Value Health. 2017 Jan;20(1):32-39.

Johnson FR, Zhou M. Patient Preferences in Regulatory Benefit-Risk Assessments: A US PerspectiveValue in Health. 2016;19(6):741-745.

Mühlbacher A, Johnson FR. Choice Experiments to Quantify Preferences for Health and Healthcare: State of the Practice. Applied Health Economics and Health Policy, 2016. 14(3): 253-266.

Mühlbacher A, Bethge S, Reed SD, Schulman KA. Patient preferences for features of health care delivery systems: A discrete-choice experiment. Health Services Research. 2016;51(2):704-27.

Gonzalez JM, Johnson FR, McAteer H, Posner J, Mughal F. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the UK: results from a discrete-choice experiment. British Journal of Dermatology2016 Jun 13. doi: 10.1111/bjd.14798.

Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, IJzerman MJ, Bridges JFP. Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health 2016;19:300-15.

Yang JC, Johnson FR, Kilambi V, Mohamed AF. Sample size and utility-difference precision in discrete-choice experiments: A meta-simulation approachJournal of  Choice Modelling. 2015;16:50-57.

Zhang J, Johnson FR, Mohamed AF, Hauber AB.  Too Many Attributes: A Test of the Validity of Combining Discrete-Choice and Best-Worst Scaling Data.J Choice Modelling. 2015;15:1-13.

Gonzalez JM, Hauber AB, Johnson FR. Estimating conditional certainty equivalents using choice-experiment data. J Choice Model. 2015;15:14-25.

Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29:2984-93.

Havrilesky LJ, Secord AA, Ehrisman JA, Berchuck A, Valea FA, Lee PS, Gaillard S, Samsa G, Cella D, Weinfurt KP, Abernethy AP, Reed SD. A conjoint analysis of the preferences of women with ovarian cancer for attributes of treatment and  disease. Cancer. 2014;120(23):3651-9.

Johnson FR, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, Bresnahan BW, Kanninen B, and Bridges JFP. Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental  Design Good Research Practices Task Force. Value in Health 2013;16(1): 3-13.

Van Houtven G, Johnson FR, Kilambi V, Hauber AB. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Medical Decision Making. 2011;31(3):469-80.

Johnson FR, Hauber AB, Özdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. Journal of Managed Care Pharmacy. 2010;16(8):616-28.

Hauber AB, Johnson FR, Özdemir S. Using conjoint analysis to estimate healthy-year equivalents for acute conditions: An application to vasomotor symptoms.Value in Health. 2009;12(1):146-52.

Johnson FR, Özdemir S, Mansfield CA, Hass S, Miller DW, Siegel CA, Sands BE.  Crohn’s disease patients’ benefit-risk preferences: Serious adverse event risks  versus treatment efficacy. Gastroenterology. 2007;133(3):769-79.

Johnson FR, Hauber AB, Osoba D, Hsu MA, Coombs J, Copley-Merriman C. Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach.Quality of Life Research. 2006;15(2):285-98.